Qualcomm Announces Quarterly Cash Dividend
17.1.2025 16:00:00 EET | Business Wire | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.85 per common share, payable on March 27, 2025, to stockholders of record at the close of business on March 6, 2025.
About Qualcomm
Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Our proven solutions drive transformation across major industries, and our Snapdragon® branded platforms power extraordinary consumer experiences. Building on our nearly 40-year leadership in setting industry standards and creating era-defining technology breakthroughs, we deliver leading edge AI, high-performance, low-power computing, and unrivaled connectivity. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress.
Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of our engineering and research and development functions and substantially all of our products and services businesses, including our QCT semiconductor business. Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patents are licensed by Qualcomm Incorporated. For more information, visit www.qualcomm.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250117738250/en/
Contacts
Qualcomm Contact:
Mauricio Lopez-Hodoyan, Investor Relations
Phone: 1-858-658-4813
Email: ir@qualcomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Completes Acquisition of PEAK:AIO to Accelerate Zettabyte-scale AI Deployments2.11.2026 15:00:00 EET | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it completed the acquisition of PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. With this acquisition, NetApp can leverage metadata services and parallel namespace innovations to power the fastest storage on the planet, NetApp Novus, to support zettabyte-scale file systems for the most demanding workloads of AI clouds and GPU-as-a-service providers. For the best AI infrastructure economics, organizations need to keep GPU resources continuously supplied with data without bottlenecks. The acquisition advances NetApp’s strategy for the next phase of AI infrastructure by bringing PEAK:AIO’s metadata and parallel file system expertise together with NetApp ONTAP, giving customers a path to AI-scale storage that combines high concurrency and massive namespace growth with the resilience, security, and operational simplicity enterprises already trust
HistoSonics Receives Regulatory Approval in Singapore, Advancing Expansion Across Asia-Pacific2.11.2026 15:00:00 EET | Press release
HistoSonics today announced that the company has received market authorization from Singapore’s Health Sciences Authority (HSA) for its Edison® Histotripsy System (under the device name HistoSonics Histotripsy System), marking another significant milestone in the company’s continued international expansion and creating new opportunities to advance access to histotripsy throughout the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102090757/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image-guided platform that uses the mechanical properties of focused ultrasound, known as histotripsy, to mechanically destroy and liquefy unwanted tissue and tumors. The technology offers a fundamentally new approach to tissue destruction without the need for invasive procedures, radiation, or thermal energy. The Edison System is currently authorized for the destruction of liver
Bentley Systems Announces Seequent’s Acquisition of Seismic Interpretation Software Company Eliis2.11.2026 15:00:00 EET | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that Seequent, The Bentley Subsurface Company, has acquired seismic interpretation software company Eliis. The acquisition will enrich Seequent’s capabilities in geophysics with seismic data interpretation and further advance subsurface understanding to help solve complex global challenges. Eliis’ global team of more than 100 geoscientists, technical specialists, and researchers will join Seequent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029964674/en/ 3D view from PaleoScan showcasing recent advancements in seismic interpretation workflows that support prospect evaluation and exploration decision-making Founded in 2007 and with headquarters in Montpellier, France, Eliis develops advanced seismic interpretation software that helps geoscientists process and analyze seismic imaging data to build detailed model
NIQ Publishes 2026 ESG Progress Report, Highlighting Action Across Climate, People, Communities, and Responsible AI2.11.2026 13:45:00 EET | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2026 Environmental, Social and Governance (ESG) Progress Report, detailing the company’s progress on key ESG priorities throughout 2025. The report covers NIQ’s efforts across environmental responsibility, its people and communities, data integrity, and responsible AI. Key highlights from 2025 include: Strengthened its approach to climate risk and environmental measurement: NIQ conducted its first climate risk assessment aligned with Task Force on Climate-related Financial Disclosures (TCFD) recommendations, tracked Scope 1, 2 and 3 emissions under the GHG Protocol, and externally verified its carbon footprint. Invested in associate development, engagement and well-being: Internal mobility increased to 35%, up from 30%, while performance review completion reached 99% and the employee survey response rate reached 89%. NIQ also introduced three new leadership development tracks, while Employee Assistance Program
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer2.11.2026 13:42:00 EET | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone or in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable, locally advanced colon cancer. The manuscript, titled “Preoperative botensilimab with or without balstilimab for patients with resectable, locally advanced pMMR or dMMR colon cancer: the UNICORN trial by GONO,” was published in Nature Medicine and is available at DOI 10.1038/s41591-026-04710-1. The UNICORN trial enrolled 56 patients in four non-randomized cohorts of 14, evaluating BOT alone or BOT+BAL in mismatch repair proficient/microsatellite stable (pMMR/MSS) and mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) colon cancer. The study ass
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom